Key facts
- This page summarizes Scott Tuten's Form 4 filing for Danimer Scientific, Inc. (DNMRQ).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 05 Apr 2024, 17:00.
Scott Tuten - 03 Apr 2024 Form 4 Insider Report for Danimer Scientific, Inc. (DNMRQ)
- Reporting relationship
- Chief Marketing Officer
- Issuer ticker
- DNMRQ
- Reported as of
- 03 Apr 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 05 Apr 2024, 17:00:10 UTC
- Prior SEC filing
- 02 Jan 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Stephen A. Martin, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Scott Tuten filed Form 4 for Danimer Scientific, Inc. (DNMRQ) on 05 Apr 2024.
Change
- Previous filing in this sequence was filed on 02 Jan 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
DNMR
transaction
Derivative
Stock Appreciation Rights
Award
- Transaction value
- $0
- Shares
- +263,410
- Change %
- Price
- $0.000000
- Shares after
- 263,410
- Date
- 03 Apr 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 263,410
- Exercise price
- $1.06
- Footnotes
- F1
DNMR
transaction
Derivative
Performance Stock Award
Award
- Transaction value
- $0
- Shares
- +151,585
- Change %
- Price
- $0.000000
- Shares after
- 151,585
- Date
- 03 Apr 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 151,585
- Exercise price
- $0.000000
- Footnotes
- F2, F3, F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
These stock appreciation rights (SARs) to purchase shares of the Issuer's Class A common stock ("Common Stock") were granted to Reporting Person on April 3, 2024 under the Danimer Scientific, Inc. 2020 Long-Term Incentive Plan (the "Plan"). SARs to purchase 87,803 shares of the Issuer's Common Stock will vest and become exercisable on each of April 3, 2025 and April 3, 2026 and 87,804 shares of the Issuer's Common Stock will vest and become exercisable on April 3, 2027.
Footnote F2
Comprised of a performance stock award (the "PSA") granted under the Plan consisting of 151,585 performance shares of the Common Stock (the "Performance Shares").
Footnote F3
Under the PSA, the Performance Shares will be issued only if they have vested in accordance with the following vesting criteria: (i) 50% of the Performance Shares (the "Total PHA Revenue Metric Shares") shall be subject to vesting upon achievement of the Total PHA Revenue metric as follows: the threshold for vesting the Total PHA Revenue Metric Shares shall be the Company achieving Total PHA Revenue of at least $135 million, in which event 50% of the Total PHA Revenue Shares Metric Shares shall vest, and upon the Company achieving Total PHA Revenue of $157 million, 100% of the Total PHA Revenue Metric Shares shall vest, with pro-rata vesting of the Total PHA Revenue Metric Shares for any amount of Total PHA Revenue in between such ranges. Total PHA Revenue shall mean the Total PHA Revenue for the Company measured based on the Company's audited consolidated financial statements for the fiscal year ended December 31, 2026.
Footnote F4
(ii) (50%) of the Performance Shares (the "Adjusted EBITDA Metric Shares") shall be subject to vesting upon achievement of the earnings before interest, taxes, depreciation and amortization, including all adjustments made for reporting this metric in public filings ("Adjusted EBITDA") metric as follows: the threshold for vesting the Adjusted EBITDA Metric Shares shall be the Company achieving Adjusted EBITDA of at least $17.2 million, in which event 50% of the Adjusted EBITDA Metric Shares shall vest, and upon the Company achieving Adjusted EBITDA of $22.3 million, 100% of the Adjusted EBITDA Metric Shares shall vest, with pro-rata vesting of the Adjusted EBITDA Metric Shares for any amount of Adjusted EBITDA in between such ranges. Adjusted EBITDA shall mean the Adjusted EBITDA for the Company measured based on the Company's audited consolidated financial statements for the fiscal year ended December 31, 2026.
Footnote F5
The earlier of April 3, 2027 or the Reporting Person's Termination Date (as defined in the Plan).